01—Abstract
Summary
Summary of the 8-K filed July 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Omega Healthcare Investors, Inc. (NYSE: OHI) reported second quarter 2026 results on July 29, 2026.
Net income was $380 milliona, or $1.19 per diluted share, compared with $140 million, or $0.46 per diluted share, in Q2 2025. The quarter was lifted by a $246.5 million gain on assets sold, which accompanied the sale of 26 facilities for $562.6 million. Adjusted FFO was $261 million, or $0.83 per diluted share, compared with $232 million, or $0.77 per diluted share, a year earlier.
FAD was $248 millionb, or $0.78 per diluted share, and NOI was $331 million, compared with $281 million in Q2 2025. Management stated that FAD per share rose 6.3% year over year. Omega completed $126 million of new investments in Q2 2026, mainly $110 million of real estate acquisitions and $16 million of real estate loan fundings, and completed another $93 million in July 2026.
Management said the pipeline supports a significant increase in capital deployment through the rest of 2026 and into early 2027, although it does not provide specific acquisition guidance. The company also said it had transitioned 20 Ciena-operated Laurels skilled nursing facilities to new operators and the Saber PropCo JV, and that it holds a 9.9% equity interest in Saber. The board raised the quarterly common dividend by $0.01 to $0.68c per share, payable August 14, 2026, and the 2026 Adjusted FFO guidance range was increased to $3.22 to $3.26 per diluted share from $3.19 to $3.25.
As of June 30, 2026, the company had $4.1 billiond of outstanding indebtedness at a weighted average interest rate of 4.2%, cash of $39.0 million, and $2.0 billion of undrawn revolver capacity. The company also reported that Genesis, which filed for Chapter 11 in July 2025, has continued to make required contractual rent and interest payments through July 2026.
02—Key points
Key Highlights
- Net income of $380 million ($1.19 per diluted share) in Q2 2026, versus $140 million ($0.46 per diluted share) in Q2 2025, including a $246.5 million gain on assets sold.
- Adjusted FFO of $261 million ($0.83 per diluted share) versus $232 million ($0.77 per diluted share) in Q2 2025; FAD of $248 million ($0.78 per diluted share) versus $223 million ($0.74 per diluted share).
- 2026 Adjusted FFO guidance raised to $3.22 to $3.26 per diluted share from $3.19 to $3.25.
- Quarterly common dividend increased by $0.01 to $0.68 per share, effective August 3, 2026, with payment on August 14, 2026.
- Sold 26 facilities for $562.6 million in Q2 2026, including 18 CommuniCare facilities for $479.9 million gross proceeds.
- Completed $126 million of Q2 2026 investments and $93 million of July 2026 investments, including the first UK care home operating company acquisition.
- Balance sheet as of June 30, 2026: $4.1 billion of indebtedness at a 4.2% weighted average interest rate, $39.0 million of cash, and $2.0 billion of undrawn revolver capacity.
03—Questions
Frequently Asked Questions
How did Omega perform on a per-share basis in Q2 2026?
Adjusted FFO was $0.83 per diluted share, compared with $0.77 in Q2 2025, and FAD was $0.78 per diluted share, compared with $0.74. Management stated that FAD per share was up 6.3% over the same quarter last year. Diluted net income was $1.19 per share, which includes the $246.5 million gain on assets sold.
What drove the increase in net income?
Net income was $380 million in Q2 2026, compared with $140 million in Q2 2025. The filing attributes a $246.5 million gain on assets sold to the quarter, largely tied to the sale of 26 facilities for $562.6 million. Rental income rose to $262.7 million from $235.6 million, and NOI rose to $331 million from $281 million.
Did management change its outlook?
Yes. The 2026 Adjusted FFO guidance range was raised to $3.22 to $3.26 per diluted share from $3.19 to $3.25. The guidance assumes no additional operators are placed on a cash basis, Genesis continues to pay $13.3 million per quarter, and Maplewood pays $19.6 million per quarter. It excludes acquisitions, capital markets activity, and provisions for credit losses.
What is the status of Genesis and Saber?
Genesis, which filed for Chapter 11 on July 9, 2025, has made all required contractual rent and interest payments through July 2026. Omega had $8.7 million outstanding under the DIP financing and $139.8 million of principal under two secured term loans as of June 30, 2026. Omega acquired a 9.9% equity interest in Saber in Q1 2026, and 27 facilities were added to Saber's operations in Q2 2026 and July 2026 through the Ciena Laurels transactions and related Saber PropCo JV acquisitions.
How is the company funded and how leveraged is it?
As of June 30, 2026, Omega had $4.1 billion of outstanding indebtedness at a weighted average annual interest rate of 4.2%, consisting of $3.8 billion of senior unsecured notes, $6.0 million on its revolver, and a $300.0 million term loan. It held $39.0 million of cash and had $2.0 billion of undrawn revolver capacity. In Q2 2026 it issued 1.3 million common shares for gross proceeds of $62 million, including $160.5 million of gross proceeds from the ATM program year to date.
04—Continue